Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

Phase 2 Completed 58 enrolled Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

RandomizedParallel-groupDouble-blindPrevention

Summary

This is a prospective single center, randomized, double-blind, 3 arm placebo-controlled study in subjects with migraine headache requiring prophylactic treatment. The patients will be randomized to receive Nicotinic Acid Extended-release tablet 500 mg or 1000 mg or placebo for 12 weeks. The safety and efficacy outcome measures will be assessed at baseline and 12 weeks.

Timeline

Start: 2022-11-25
Primary completion: 2024-01-10
Completion: 2024-01-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Niacin	Small molecule	500 mg	Oral
Comparator	Niacin	Small molecule	1000 mg	Oral

Indications

No indication recorded.